iDose TREX travoprost intracameral implant Updated Aug 27
Monitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.
- iDose TREX has nearly double the drug capacity of the already-approved iDose TR, potentially offering longer-lasting IOP control and a competitive advantage in the glaucoma implant market.
- The first-generation iDose TR is already FDA-approved and commercially launched, providing a clinical and regulatory de-risking pathway for iDose TREX.
- Analyst consensus is Strong Buy (18 buy/strong buy vs 2 hold and 1 sell) with a mean price target of $197.15, implying ~8% upside from the current ~$180.57 price.
- iDose TREX is still in Phase 2b/3 with no specific topline readout date announced, meaning a potential approval is likely years away (2028-2030 at earliest).
- Multiple insiders (President & COO, directors) have been selling shares in recent months, with transactions totaling over $1M at prices around $150-190.
- Short interest stands at ~6.70% of outstanding shares (5.21 days to cover), indicating some bearish positioning.